Trientine Clinical Trials (2026): 11 Studies for Wilson Disease & Diabetic Retinopathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
11 Trientine clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Wilson Disease & Diabetic Retinopathy) and 487 total planned enrollment. 1 Phase 3 Trientine trial and 2 Phase 2, 1 Phase 4 are listed. Most recent activity: NCT04706429 (Jul 2024).
Trientine clinical trials at a glance: phase × recruitment status
| Phase | completed | terminated | withdrawn | unknown | Total |
|---|---|---|---|---|---|
| P1 | 2 | 1 | 3 | ||
| P1/P2 | 1 | 1 | |||
| P2 | 1 | 1 | 2 | ||
| P3 | 1 | 1 | |||
| P4 | 1 | 1 | |||
| N/A | 2 | 1 | 3 |
Trientine clinical trials by indication
Wilson Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02426905 | — | P4 | unknown | Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine |
| NCT01472874 | — | N/A | completed | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease |
| NCT00004339 | — | P3 | completed | Study of Tetrathiomolybdate in Patients With Wilson Disease |
Hypertrophic Cardiomyopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04706429 | TEMPEST | P2 | completed | The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy |
Trientine Treatment for Wilson's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03299829 | — | N/A | completed | A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients |
Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02068079 | — | P1 | withdrawn | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma |
Wilson's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01874028 | — | P1 | completed | A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients |
Ovarian Neoplasms Malignant (Excl Germ Cell) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03480750 | Trientine | P1/P2 | completed | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer |
Diabetic Retinopathy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01213888 | — | N/A | terminated | Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy |
Advanced Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01178112 | — | P1 | completed | Trientine and Carboplatin in Advanced Malignancies |
Macular Edema Following Cataract Surgery (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01295073 | — | P2 | withdrawn | Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus |
Trientine pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| TEMPEST | NCT04706429 | P2 | completed | Hypertrophic Cardiomyopathy | 154 | PMID 37137675 |
Terminated and withdrawn Trientine trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT02068079withdrawnA Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma
- NCT01213888terminatedTrientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
- NCT01295073withdrawnTrientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus
All Trientine trials (11)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04706429 | TEMPEST | The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy | P2 | completed | 154 | Manchester University NHS Foundation Trust | Dec 2020 |
| NCT03480750 | Trientine | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer | P1/P2 | completed | 18 | National Cheng-Kung University Hospital | Sep 2012 |
| NCT03299829 | A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients | — | completed | 48 | Excelsior | Jan 2018 | |
| NCT02426905 | Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine | P4 | unknown | 90 | Univar BV | Jan 2016 | |
| NCT02068079 | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | P1 | withdrawn | 0 | Duke University | Apr 2014 | |
| NCT01178112 | Trientine and Carboplatin in Advanced Malignancies | P1 | completed | 56 | M.D. Anderson Cancer Center | Jul 2010 | |
| NCT01874028 | A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients | P1 | completed | 20 | Univar BV | May 2013 | |
| NCT01213888 | Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy | N/A | terminated | 3 | University of British Columbia | Nov 2010 | |
| NCT01472874 | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease | N/A | completed | 8 | Yale University | Jan 2010 | |
| NCT01295073 | Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus | P2 | withdrawn | 0 | University of British Columbia | — | |
| NCT00004339 | Study of Tetrathiomolybdate in Patients With Wilson Disease | P3 | completed | 90 | National Center for Research Resources (NCRR) | Jan 1994 |
Trientine clinical trials: frequently asked questions
- How many Trientine clinical trials are there?
- 11 Trientine clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are marked completed.
- Are Trientine clinical trials recruiting in 2026?
- No active Trientine trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Trientine being studied for?
- Trientine is being studied for Wilson Disease, Diabetic Retinopathy, Fallopian Tube Cancer, Hypertrophic Cardiomyopathy, Macular Edema Following Cataract Surgery and 6 more. The trials are grouped by indication on this page.
- What phase is Trientine in?
- Trientine clinical trials span 1 Phase 4, 1 Phase 3, 2 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Trientine clinical trials?
- The lead sponsor across the most Trientine trials is University of British Columbia, with 8 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Trientineas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: